These omega-3 fish-oil fats most dependably lower blood fats, with modest support for lower blood pressure and eased low mood. Protection against heart-related death and mental decline is mixed, and a longer lifespan stays unproven. Higher doses can trigger an irregular heartbeat; freshness matters, and blood-thinner users may bruise more easily. (Full Review)

Protocol

Maintenance Dose

250–500 mg/day

Combined EPA+DHA; often aiming for an omega-3 index above 8%

Therapeutic Dose

2–4 g/day

For triglyceride lowering; 1–2 g/day EPA-predominant for mood support

Administration

With fattiest meal

Split larger daily doses across meals to improve absorption and tolerance

Time to effect

Triglycerides

Within weeks

Blood fats begin to fall

Mood

4–8 weeks

Depressive symptoms, when present

Omega-3 Index

3–4 months

Membrane omega-3 status stabilizes

Benefits

High: Triglyceride reduction

Medium: Reduced cardiovascular events in high-risk high-triglyceride patients (conflicted); lower blood pressure; reduced depressive symptoms

Low: Reduced coronary heart disease mortality; rheumatoid arthritis symptom relief; slower cognitive decline & dementia risk (conflicted)

Speculative: All-cause mortality & longevity extension; preservation of lean muscle mass in aging

Contraindications

History of atrial fibrillation or high arrhythmia risk (esp. ≥1 g/day)

Bleeding disorders or multiple blood thinners

Within ~7 days of major surgery

Fish or shellfish allergy

Severe hepatic impairment

Key Interactions

Prescription anticoagulants and antiplatelets: warfarin, direct oral anticoagulants (apixaban, rivaroxaban), and antiplatelets (clopidogrel)

Over-the-counter analgesics: aspirin and NSAIDs (ibuprofen, naproxen)

Blood-thinning supplements: Ginkgo biloba, garlic extract, high-dose vitamin E, and nattokinase

Additive (beneficial-overlap) supplements and drugs: niacin, fibrates, and antihypertensive medications

Risk & Side Effects

High: Increased risk of atrial fibrillation; gastrointestinal upset & fishy reflux

Medium: Increased bleeding tendency (conflicted); elevated LDL cholesterol (high-dose DHA)

Low: Consumption of oxidized (rancid) oil; prostate cancer association (conflicted)

Speculative: Blunted acute immune/inflammatory response

Monitoring

Marker	Target	Why
Omega-3 Index (RBC EPA+DHA)	> 8%	Reflects long-term omega-3 status and cardiovascular risk
Triglycerides	< 100 mg/dL	Primary lipid response to EPA/DHA
LDL-C (LDL cholesterol)	< 100 mg/dL (lower if high-risk)	Detects the LDL rise possible with high-dose DHA
hs-CRP (high-sensitivity C-reactive protein)	< 1 mg/L	Tracks systemic inflammation the intervention may lower
Omega-6:Omega-3 Ratio	< 4:1	Gauges dietary fat balance influencing the anti-inflammatory effect

Cadence: Baseline, then ~3–4 months after starting or changing dose, then every 6–12 months once stable

Qualitative Assessment

Mood and emotional resilience
Joint comfort and morning stiffness
Cognitive clarity and focus
Dry-eye and skin dryness
Absence of palpitations or irregular heartbeat

EPA & DHA for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment